首页> 外文期刊>Orthopaedics and trauma >(iii) Ewing's sarcoma of bone
【24h】

(iii) Ewing's sarcoma of bone

机译:(iii)尤因骨骼肉瘤

获取原文
获取原文并翻译 | 示例
           

摘要

Ewing's sarcoma is a primitive malignant bone tumour consisting of small, blue, round malignant cells that may show varying degrees of neural differentiation. It accounts for approximately 5% of all malignant bone tumours and arises most frequently in children or adolescents. Despite significant progress with the use of intensive multiagent chemotherapy and local control measures (survival rates have increased from 10-15% to 65-70% in the last 40 years), a significant proportion of patients still die of disease progression. Clinical and biological prognostic factors should be used to guide the therapeutic choices for each patient. The treatment of Ewing's sarcoma of bone is currently based on combined therapy with neoadjuvant chemotherapy, radiation therapy and surgical resection of the primary tumour. Survival in primary metastatic Ewing's sarcoma is poor (less than 30%) and new therapies are needed for these patients.
机译:尤因肉瘤是一种原始的恶性骨肿瘤,由小的,蓝色的圆形恶性细胞组成,可能显示不同程度的神经分化。它约占所有恶性骨肿瘤的5%,在儿童或青少年中最常见。尽管在使用密集多药化疗和局部控制措施方面取得了显着进展(在过去40年中,存活率从10-15%增加到65-70%),但是仍有相当一部分患者死于疾病进展。应使用临床和生物学预后因素来指导每个患者的治疗选择。目前,尤文氏骨肉瘤的治疗是基于新辅助化疗,放疗和原发肿瘤手术切除的联合治疗。原发转移性尤因氏肉瘤的存活率很低(不到30%),这些患者需要新的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号